美通社

2024-10-25 07:40

Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients

SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY® has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. Subsequently, VELSIPITY® will be introduced in other qualified hospitals under the connect policy. VELSIPITY® is now the third commercialized product of Everest Medicines.

VELSIPITY® is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau in April 2024. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active UC. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. By 2030, the number of patients with UC in China is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies.

"The launch of VELSIPITY® in the Greater Bay Area accelerates the access to this advanced therapy in mainland China, offering a new option for patients with moderately to severely active UC." Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Everest Medicines is committed to expeditiously delivering innovative therapies to patients. Moving forward, we will keep leveraging our strengths and exploring innovative ways to improve the accessibility of these therapies. We plan to have VELSIPITY® submitted for new drug application in mainland China by the end of this year, further enhancing its accessibility and benefiting more patients."

VELSIPITY® was developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022. Everest Medicines obtained exclusive rights to develop, produce, and commercialize VELSIPITY® in Greater China and South Korea from Arena as early as 2017. As a core product in the field of autoimmune diseases for Everest Medicines, VELSIPITY® was successively approved in Macau and Singapore in the first half of this year and was approved in the United States and the European Union in October last year and February this year, respectively. In addition, Everest Medicines recently submitted an new drug application for VELSIPITY® in Hong Kong, China.

VELSIPITY® is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU, and the ELEVATE UC 52 and ELEVATE UC 12 were the only studies of advanced therapies for UC to include patients with isolated proctitis. In the results of the Asian multi-center Phase 3 clinical trial of VELSIPITY® for the treatment of moderately to severely active UC announced in July this year, VELSIPITY® achieved positive topline data results in both the induction and maintenance treatment periods, with good safety profile, and is convenient to take once a day, providing further solid scientific basis and support for the wide application of the drug in clinical practice.

About VELSIPITY® (etrasimod)

VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau for VELSIPITY® in ulcerative colitis.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

source: Everest Medicines

【你點睇?】馬斯克劍指美國國家民主基金會(NED),籲網民找出「罪證」。你認為若NED遭關閉,是否可促進全球和平穩定?► 立即投票

人氣文章
最近7天
沒有相關資料。
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
4
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
5
一本萬利 | 2025年的五個「勿」(有片)
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
8
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
9
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
10
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
11
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
12
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
13
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
14
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
15
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
16
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
17
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
18
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
19
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
20
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
21
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
22
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
23
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
24
港股 | 午市前瞻 | DeepSeek概念火爆炒起AI股 百度係時候追落後
25
DeepSeek | 從私募孵化的AI新星--DeepSeek崛起之路
26
高息定存 | 信銀國際1個月加至3.85厘,華僑一年期3.6厘
27
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
28
阿里 | 推新AI模型聲稱超越DeepSeek,股價逆市飆逾半成仍有上升空間?
29
【FOCUS】中長期資金入市首提硬指標,健康慢牛仍需解兩難
30
魚缸博客 | Deepseek改變AI?繼續買芯片股!衝啊!
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

etnet榮獲第六屆國際信息商會議「最佳信息商」白金獎

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

2025-26年度財政預算案

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老